Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Aug;46(8):1025-1035.
doi: 10.1007/s00270-023-03443-9. Epub 2023 May 4.

Cost-Utility Analysis of Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms

Affiliations
Randomized Controlled Trial

Cost-Utility Analysis of Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms

Ferran Capdevila et al. Cardiovasc Intervent Radiol. 2023 Aug.

Abstract

Purpose: To perform a post hoc cost-utility analysis of a randomized controlled clinical trial comparing prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Materials and methods: We conducted a cost-utility analysis over a 5-year period to compare PAE versus TURP from a Spanish National Health System perspective. Data were collected from a randomized clinical trial performed at a single institution. Effectiveness was measured as quality-adjusted life years (QALYs), and an incremental cost-effectiveness ratio (ICER) was derived from the cost and QALY values associated with these treatments. Further sensitivity analysis was performed to account for the impact of reintervention on the cost-effectiveness of both procedures.

Results: At the 1-year follow-up, PAE resulted in mean cost per patient of €2904.68 and outcome of 0.975 QALYs per treatment. In comparison, TURP had cost €3846.72 per patient and its outcome was 0.953 QALYs per treatment. At 5 years, the cost for PAE and TURP were €4117.13 and €4297.58, and the mean QALY outcome was 4.572 and 4.487, respectively. Analysis revealed an ICER of €2121.15 saved per QALY gained when comparing PAE to TURP at long-term follow-up. Reintervention rate for PAE and TURP was 12% and 0%, respectively.

Conclusions: Compared to TURP, in short term, PAE could be considered a cost-effective strategy within the Spanish healthcare system for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. However, in long term, the superiority is less apparent due to higher reintervention rates.

Keywords: Benign prostatic hyperplasia; Cost-effectiveness; Prostatic artery embolization (PAE); Transurethral resection of the prostate (TURP).

PubMed Disclaimer

Comment in

References

    1. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148–51. - DOI - PubMed - PMC
    1. Gravas S, Cornu JN DM et al. EAU Guidelines: management of non-neurogenic male LUTS [Internet]. 2020. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
    1. Insausti I, Sáez de Ocáriz A, Galbete A, Capdevila F, Solchaga S, Giral P, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2020;31(6):882–90. - DOI - PubMed
    1. Abt D, Müllhaupt G, Hechelhammer L, Markart S, Güsewell S, Schmid H-P, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-year outcomes of a randomised, open-label single-centre trial. Eur Urol. 2021;80(1):34–42. - DOI - PubMed
    1. Gao Y, Huang Y, Zhang R, Yang Y, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate–a prospective, randomized, and controlled clinical trial. Radiology. 2014;270(3):920–8. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources